Healthcare · Drug Manufacturers - Specialty & Generic
· website
$0.04
52wk 0.03 – 0.11
Overall
25.6
Value
72.7
Growth
0.0
Health
36.5
Quality
0.0
Momentum
7.9
Dividend
—
Price
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Price analytics
Returns
1 day
2.7%
1 week
0.0%
1 month
5.6%
3 months
11.8%
6 months
-44.1%
1 year
-63.8%
3 years
-92.4%
Risk
Volatility (1y ann.)
63.7%
Beta vs ASX 200
0.36
Sharpe (1y)
-1.34
VaR 95% (1-day)
-6.5%
Max drawdown (1y)
-68.0%
Off 1-year high
-62.0%
Technicals
RSI(14)
11
OS
vs 50DMA
-4.0%
vs 200DMA
-35.7%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value72.7
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health36.5
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
95
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum7.9
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
30
Position in 52-week range
8
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).